Evidence map›Paper›PMID 41807658›Full record

ArticleAnnals of hematology2026

Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system.

Yuta Ito, Yasunori Kogure, Akiko Miyagi Maeshima, Rika Hosoba, Suguru Fukuhara, Wataru Munakata, Kenichi Chiba, Ai Okada, Yuichi Shiraishi, Yoshitaka Narita and 2 more

Abstract readCase Reports
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuta ItoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yasunori KogureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Akiko Miyagi MaeshimaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Rika HosobaDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kenichi ChibaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Ai OkadaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Yoshitaka NaritaRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan. kizutsu@ncc.go.jp.
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.

Funding

Japan Agency for Medical Research and Development JP24ck0106794h0002Japan Science and Technology Agency Moonshot R&D Program JPMJMS2022-4Japan Society for the Promotion of Science (JSPS) KAKENHI JP21H05051
6 · The paper itself

Abstract

A 62-year-old female was referred to our hospital because of left pleural effusion. She had a history of primary large B-cell lymphoma (LBCL) of the CNS (PCNSL), which was treated with chemoradiotherapy 14 years ago. Imaging studies revealed no other lesions. Pathologically, large atypical lymphoid cells were present in the pleural fluid and positive for CD20 and CD79a, while EBV and HHV-8 were negative. She was diagnosed with HHV8-negative effusion-based lymphoma (EBL) and achieved complete response after two cycles of rituximab monotherapy. We performed targeted-capture sequencing of lymphoma-associated genes using tumor samples from EBL and PCNSL, and detected the identical mutations in eight genes including MYD88 and CD79B. Identical arm-level copy number changes and focal deletions involving HLA-B, HLA-C, and CDKN2A, were also observed, suggesting clonal association between EBL and PCNSL. On the other hand, there were several lymphoma subtype-specific alterations, such as CARD11 and KMT2D mutations in PCNSL as well as PIM1 and PRDM1 mutations in EBL. LBCLs involving specific extranodal sites, such as CNS, testis, and adrenal gland, tend to recur in CNS, and harbors characteristic driver alterations, such as mutations in MYD88 and CD79B, similar to the MCD subtype of diffuse large B-cell lymphoma. Our genetic analysis suggests that in this case (i) PCNSL recurred as EBL or (ii) EBL developed from a common founder clone with PCNSL after long-term remission, providing insights into genetic basis underlying extranodal LBCL with CNS tropism.

Indexed as

Central Nervous System NeoplasmsLymphoma, Large B-Cell, DiffusePleural EffusionCD79 AntigensFemaleHumansMiddle AgedMutationCD79 AntigensCD79B protein, humanCD79BClonal analysisFluid overload-associated LBCLMYD88Primary LBCL of the CNS

Identifiers

PMID41807658
PMCPMC12975790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.